{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T22:09:46Z","timestamp":1783548586448,"version":"3.55.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004257","name":"Helse Vest","doi-asserted-by":"publisher","award":["F-12609"],"award-info":[{"award-number":["F-12609"]}],"id":[{"id":"10.13039\/501100004257","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004257","name":"Helse Vest","doi-asserted-by":"publisher","award":["912161"],"award-info":[{"award-number":["912161"]}],"id":[{"id":"10.13039\/501100004257","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009947","name":"Norsk Oftalmologisk Forening","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Hum Genet"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41431-025-01958-y","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:18:39Z","timestamp":1760537919000},"page":"1668-1676","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Variable response of germline activating PDGFRB variants to receptor tyrosine kinase inhibitors: implications for treatment"],"prefix":"10.1038","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1163-0393","authenticated-orcid":false,"given":"Ileana","family":"Cristea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4090-5114","authenticated-orcid":false,"given":"Roya","family":"Mehrasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8595-4489","authenticated-orcid":false,"given":"Titas","family":"Gladkauskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1025-4840","authenticated-orcid":false,"given":"Eyvind","family":"R\u00f8dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9943-9034","authenticated-orcid":false,"given":"Ove","family":"Bruland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2388-0181","authenticated-orcid":false,"given":"Cecilie","family":"Bredrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"1958_CR1","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1042\/BST20200004","volume":"48","author":"MA Rogers","year":"2020","unstructured":"Rogers MA, Fantauzzo KA. The emerging complexity of PDGFRs: activation, internalization and signal attenuation. Biochem Soc Trans. 2020;48:1167\u201376.","journal-title":"Biochem Soc Trans"},{"key":"1958_CR2","doi-asserted-by":"publisher","first-page":"F79","DOI":"10.1016\/S0304-419X(98)00015-8","volume":"1378","author":"C-H Heldin","year":"1998","unstructured":"Heldin C-H, \u00d6stman A, R\u00f6nnstrand L. Signal transduction via platelet-derived growth factor receptors. Biochimica et Biophys Acta (BBA) - Rev Cancer. 1998;1378:F79\u2013F113.","journal-title":"Biochimica et Biophys Acta (BBA) - Rev Cancer"},{"key":"1958_CR3","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1101\/gad.1653708","volume":"22","author":"J Andrae","year":"2008","unstructured":"Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008;22:1276\u2013312.","journal-title":"Genes Dev"},{"key":"1958_CR4","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1007\/s00018-020-03753-y","volume":"78","author":"E Gu\u00e9rit","year":"2021","unstructured":"Gu\u00e9rit E, Arts F, Dachy G, Boulouadnine B, Demoulin J-B. PDGF receptor mutations in human diseases. Cellular Mol Life Sci. 2021;78:3867\u201381.","journal-title":"Cellular Mol Life Sci"},{"key":"1958_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2350\/10-12-0944-PB.1","volume":"15","author":"CM Coffin","year":"2012","unstructured":"Coffin CM, Alaggio R. Fibroblastic and myofibroblastic tumors in children and adolescents. Pediatric Dev Pathol. 2012;15:127\u201380.","journal-title":"Pediatric Dev Pathol"},{"key":"1958_CR6","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1001\/jamadermatol.2019.0114","volume":"155","author":"G Dachy","year":"2019","unstructured":"Dachy G, de Krijger RR, Fraitag S, Th\u00e9ate I, Brichard B, Hoffman SB, et al. Association of PDGFRB mutations with pediatric myofibroma and myofibromatosis. JAMA Dermatol. 2019;155:946\u201350.","journal-title":"JAMA Dermatol"},{"key":"1958_CR7","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/ajmg.c.31755","volume":"181","author":"T Takenouchi","year":"2019","unstructured":"Takenouchi T, Okuno H, Kosaki K. Kosaki overgrowth syndrome: A newly identified entity caused by pathogenic variants in platelet-derived growth factor receptor-beta. Am J Med Genet C Semin Med Genet. 2019;181:650\u20137.","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"1958_CR8","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.ajhg.2015.07.009","volume":"97","author":"JJ Johnston","year":"2015","unstructured":"Johnston JJ, Sanchez-Contreras MY, Keppler-Noreuil KM, Sapp J, Crenshaw M, Finch NA, et al. A point mutation in PDGFRB causes autosomal-dominant penttinen syndrome. Am J Hum Genet. 2015;97:465\u201374.","journal-title":"Am J Hum Genet"},{"key":"1958_CR9","doi-asserted-by":"crossref","unstructured":"Bredrup C, Cristea I, Safieh LA, Di Maria E, Gjertsen BT, Tveit KS, et al. Temperature-dependent autoactivation associated with clinical variability of PDGFRB Asn666 substitutions. Hum Mol Genet. 2021;30:72\u20137.","DOI":"10.1093\/hmg\/ddab014"},{"key":"1958_CR10","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/gim.2017.104","volume":"20","author":"D Pond","year":"2018","unstructured":"Pond D, Arts FA, Mendelsohn NJ, Demoulin JB, Scharer G, Messinger Y. A patient with germ-line gain-of-function PDGFRB p.N666H mutation and marked clinical response to imatinib. Genet Med. 2018;20:142\u201350.","journal-title":"Genet Med"},{"key":"1958_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2023.100444","volume":"4","author":"A Howaldt","year":"2024","unstructured":"Howaldt A, Lenglez S, Velmans C, Schultheis AM, Clahsen T, Matthaei M, et al. Corneal infantile myofibromatosis caused by novel activating imatinib-responsive variants in PDGFRB. Ophthalmol Sci. 2024;4:100444.","journal-title":"Ophthalmol Sci"},{"key":"1958_CR12","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1111\/bjd.19717","volume":"184","author":"A Onoufriadis","year":"2021","unstructured":"Onoufriadis A, Boulouadnine B, Dachy G, Higashino T, Huang HY, Hsu CK, et al. A germline mutation in the platelet-derived growth factor receptor beta gene may be implicated in hereditary progressive mucinous histiocytosis. British J Dermatol. 2021;184:967\u201370.","journal-title":"British J Dermatol"},{"key":"1958_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1167\/iovs.64.14.9","volume":"64","author":"T Gladkauskas","year":"2023","unstructured":"Gladkauskas T, Bruland O, Abu Safieh L, Edward DP, R\u00f8dahl E, Bredrup C. Corneal vascularization associated with a novel PDGFRB variant. Invest Ophthalmol Vis Sci. 2023;64:9.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1958_CR14","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1002\/ajmg.a.62264","volume":"185","author":"CF Rustad","year":"2021","unstructured":"Rustad CF, Tveten K, Prescott TE, Bjerkeseth PO, Bredrup C, Pfeiffer HCV. Positive response to imatinib in PDGFRB-related Kosaki overgrowth syndrome. Am J Med Genet A. 2021;185:2597\u2013601.","journal-title":"Am J Med Genet A"},{"key":"1958_CR15","doi-asserted-by":"crossref","unstructured":"Barry KK, Schienda J, Morrow JJ, Al-Ibraheemi A, Balkin DM, Church AJ, et al. Genomic analysis reveals germline and somatic PDGFRB variants with clinical implications in familial infantile myofibromatosis. Pediatric Blood Cancer. 2023;70:e30262.","DOI":"10.1002\/pbc.30262"},{"key":"1958_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3115-x","volume":"17","author":"P Mudry","year":"2017","unstructured":"Mudry P, Slaby O, Neradil J, Soukalova J, Melicharkova K, Rohleder O, et al. Case report: rapid and durable response to PDGFR targeted therapy in a child with refractory multiple infantile myofibromatosis and a heterozygous germline mutation of the PDGFRB gene. BMC Cancer. 2017;17:119.","journal-title":"BMC Cancer"},{"key":"1958_CR17","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1002\/ajmg.a.62603","volume":"188","author":"H Iznardo","year":"2022","unstructured":"Iznardo H, Bredrup C, Bernal S, Gladkauskas T, Mascar\u00f3 JM Jr, Ro\u00e9 E, et al. Clinical and molecular response to dasatinib in an adult patient with Penttinen syndrome. Am J Med Genet A. 2022;188:1233\u20138.","journal-title":"Am J Med Genet A"},{"key":"1958_CR18","doi-asserted-by":"crossref","unstructured":"Bredrup C, Stokowy T, McGaughran J, Lee S, Sapkota D, Cristea I, et al. A tyrosine kinase-activating variant Asn666Ser in PDGFRB causes a progeria-like condition in the severe end of Penttinen syndrome. Eur J Human Genet. 2019;27;574\u201381.","DOI":"10.1038\/s41431-018-0323-z"},{"key":"1958_CR19","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1038\/onc.2015.383","volume":"35","author":"FA Arts","year":"2016","unstructured":"Arts FA, Chand D, Pecquet C, Velghe AI, Constantinescu S, Hallberg B, et al. PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib. Oncogene. 2016;35:3239\u201348.","journal-title":"Oncogene"},{"key":"1958_CR20","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1093\/hmg\/ddx081","volume":"26","author":"FA Arts","year":"2017","unstructured":"Arts FA, Sciot R, Brichard B, Renard M, de Rocca Serra A, Dachy G, et al. PDGFRB gain-of-function mutations in sporadic infantile myofibromatosis. Hum Mol Genet. 2017;26:1801\u201310.","journal-title":"Hum Mol Genet"},{"key":"1958_CR21","doi-asserted-by":"publisher","first-page":"3902","DOI":"10.1111\/jcmm.17427","volume":"26","author":"A N\u00e9d\u00e9lec","year":"2022","unstructured":"N\u00e9d\u00e9lec A, Gu\u00e9rit EM, Dachy G, Lenglez S, Wong LokS, Arts FA, et al. Penttinen syndrome-associated PDGFRB Val665Ala variant causes aberrant constitutive STAT1 signalling. J Cell Mol Med. 2022;26:3902\u201312.","journal-title":"J Cell Mol Med"},{"key":"1958_CR22","doi-asserted-by":"crossref","unstructured":"Sramek M, Neradil J, Macigova P, Mudry P, Polaskova K, Slaby O, et al. Effects of sunitinib and other kinase inhibitors on cells harboring a PDGFRB mutation associated with infantile myofibromatosis. Int J Mol Sci. 2018;19:2599.","DOI":"10.3390\/ijms19092599"},{"key":"1958_CR23","doi-asserted-by":"publisher","first-page":"8392","DOI":"10.1073\/pnas.90.18.8392","volume":"90","author":"WS Pear","year":"1993","unstructured":"Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proceedings Natl Acad Sci USA. 1993;90:8392\u20136.","journal-title":"Proceedings Natl Acad Sci USA"},{"key":"1958_CR24","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11481-013-9484-2","volume":"9","author":"CH Heldin","year":"2014","unstructured":"Heldin CH. Targeting the PDGF signaling pathway in the treatment of non-malignant diseases. J Neuroimmune Pharm. 2014;9:69\u201379.","journal-title":"J Neuroimmune Pharm"},{"key":"1958_CR25","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1002\/ajmg.a.61615","volume":"182","author":"TL Wenger","year":"2020","unstructured":"Wenger TL, Bly RA, Wu N, Albert CM, Park J, Shieh J, et al. Activating variants in PDGFRB result in a spectrum of disorders responsive to imatinib monotherapy. Am J Med Genet A. 2020;182:1576\u201391.","journal-title":"Am J Med Genet A"},{"key":"1958_CR26","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/sj.leu.2404897","volume":"22","author":"S Shukla","year":"2008","unstructured":"Shukla S, Sauna ZE, Ambudkar SV. Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2. Leukemia. 2008;22:445\u20137.","journal-title":"Leukemia"},{"key":"1958_CR27","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1038\/s41375-023-02045-1","volume":"37","author":"J Hofmann","year":"2023","unstructured":"Hofmann J, Bart\u016fn\u011bk A, Hauser T, Sedmak G, Ber\u00e1nek J, Ry\u0161\u00e1nek P, et al. Dasatinib anhydrate containing oral formulation improves variability and bioavailability in humans. Leukemia. 2023;37:2486\u201392.","journal-title":"Leukemia"},{"key":"1958_CR28","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1517\/17425255.2010.506873","volume":"6","author":"DR Duckett","year":"2010","unstructured":"Duckett DR, Cameron MD. Metabolism considerations for kinase inhibitors in cancer treatment. Expert Opin Drug Metab Toxicol. 2010;6:1175\u201393.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1958_CR29","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1182\/blood.V108.11.1386.1386","volume":"108","author":"S Okabe","year":"2006","unstructured":"Okabe S, Tauchi T, Broxmeyer HE, Ohyashiki K. Mechanism of drug resistance to dasatinib (BMS-354825) and imatinib in chronic myelogenous leukemia cells. Blood. 2006;108:1386.","journal-title":"Blood"},{"key":"1958_CR30","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/gtc.12022","volume":"18","author":"D Kitagawa","year":"2013","unstructured":"Kitagawa D, Yokota K, Gouda M, Narumi Y, Ohmoto H, Nishiwaki E, et al. Activity-based kinase profiling of approved tyrosine kinase inhibitors. Genes Cells. 2013;18:110\u201322.","journal-title":"Genes Cells"},{"key":"1958_CR31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","volume":"103","author":"R Roskoski","year":"2016","unstructured":"Roskoski R. Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. Pharmacological Res. 2016;103:26\u201348.","journal-title":"Pharmacological Res"},{"key":"1958_CR32","doi-asserted-by":"publisher","first-page":"858","DOI":"10.2340\/00015555-2671","volume":"97","author":"C Lepelletier","year":"2017","unstructured":"Lepelletier C, Al-Sarraj Y, Bodemer C, Shaath H, Fraitag S, Kambouris M, et al. Heterozygous PDGFRB mutation in a three-generation family with autosomal dominant infantile myofibromatosis. Acta Derm Venereol. 2017;97:858\u20139.","journal-title":"Acta Derm Venereol"},{"key":"1958_CR33","first-page":"49","volume":"63","author":"N Ito","year":"2019","unstructured":"Ito N, Watanabe S, Mishima H, Kinoshita A, Okada M, Moriuchi H, et al. A mutation in PDGFRB in a family with infantile myofibromatosis. Acta Med Nagasakiensia. 2019;63:49\u201353.","journal-title":"Acta Med Nagasakiensia"},{"key":"1958_CR34","doi-asserted-by":"publisher","first-page":"173","DOI":"10.11648\/j.ajp.20200602.30","volume":"6","author":"E Ortiz","year":"2020","unstructured":"Ortiz E, Kochhar A, Chandrasekar I. Invasive myofibromatosis with visceral involvement in a term newborn: a case report. Am J Pediatrics. 2020;6:173\u20137.","journal-title":"Am J Pediatrics"},{"key":"1958_CR35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40348-021-00117-9","volume":"8","author":"T R\u00f6mer","year":"2021","unstructured":"R\u00f6mer T, Wagner N, Braunschweig T, Meyer R, Elbracht M, Kontny U, et al. Aggressive infantile myofibromatosis with intestinal involvement. Mol Cell Pediatr. 2021;8:7.","journal-title":"Mol Cell Pediatr"},{"key":"1958_CR36","doi-asserted-by":"crossref","unstructured":"Elsbernd A, Boulouadnine B, Ahmed A, Farooqi M, Sandritter T, Shakhnovich V, et al. Novel Oncogenic PDGFRB Variant in Severe Infantile Myofibromatosis With Response to Imatinib Using Therapeutic Drug Monitoring. JCO Precision Oncology. 2022;6:e2200250.","DOI":"10.1200\/PO.22.00250"},{"key":"1958_CR37","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jpeds.2014.10.015","volume":"166","author":"T Takenouchi","year":"2015","unstructured":"Takenouchi T, Yamaguchi Y, Tanikawa A, Kosaki R, Okano H, Kosaki K. Novel overgrowth syndrome phenotype due to recurrent de novo PDGFRB mutation. Journal Pediatrics. 2015;166:483\u20136.","journal-title":"Journal Pediatrics"},{"key":"1958_CR38","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/cge.13752","volume":"98","author":"A Foster","year":"2020","unstructured":"Foster A, Chalot B, Antoniadi T, Schaefer E, Keelagher R, Ryan G, et al. Kosaki overgrowth syndrome: A novel pathogenic variant in PDGFRB and expansion of the phenotype including cerebrovascular complications. Clinical Genet. 2020;98:19\u201331.","journal-title":"Clinical Genet"},{"key":"1958_CR39","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jpra.2020.07.001","volume":"25","author":"H Walker","year":"2020","unstructured":"Walker H, Foster A, Cole T, Jester A. Carpal tunnel syndrome in paediatric patients: A novel association with Kosaki overgrowth syndrome. JPRAS Open. 2020;25:83\u20137.","journal-title":"JPRAS Open"},{"key":"1958_CR40","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/cge.14078","volume":"101","author":"U Hern\u00e1ndez Dorronsoro","year":"2022","unstructured":"Hern\u00e1ndez Dorronsoro U, Gawlinski P, Lasa-Aranzasti A, Mart\u00ednez-Soroa I, Artola Aizalde E, Saez Villaverde R, et al. Kosaki overgrowth syndrome due to a novel de novo PDGFRB variant. Clinical Genet. 2022;101:144\u20135.","journal-title":"Clinical Genet"},{"key":"1958_CR41","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1159\/000517978","volume":"13","author":"H Mutlu Albayrak","year":"2022","unstructured":"Mutlu Albayrak H, Calder AD. Kosaki overgrowth syndrome: report of a family with a novel PDGFRB variant. Mol Syndromol. 2022;13:38\u201344.","journal-title":"Mol Syndromol"},{"key":"1958_CR42","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1002\/(SICI)1096-8628(19970317)69:2<182::AID-AJMG13>3.0.CO;2-H","volume":"69","author":"M Penttinen","year":"1997","unstructured":"Penttinen M, Niemi KM, Vinkka-Puhakka H, Johansson R, Aula P. New progeroid disorder. Am J Med Genet. 1997;69:182\u20137.","journal-title":"Am J Med Genet"},{"key":"1958_CR43","doi-asserted-by":"publisher","first-page":"912","DOI":"10.2340\/00015555-2993","volume":"98","author":"Z Zhang","year":"2018","unstructured":"Zhang Z, Zheng S, Zheng S, Wang Y, Xu XG, Gao XH, et al. Premature aging syndrome, penttinen type: report of a chinese case with a PDGFRB mutation. Acta Derm Venereol. 2018;98:912\u20133.","journal-title":"Acta Derm Venereol"},{"key":"1958_CR44","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1002\/ajmg.a.62558","volume":"188","author":"B Aggarwal","year":"2022","unstructured":"Aggarwal B, Correa ARE, Gupta N, Jana M, Kabra M. First case report of Penttinen syndrome from India. Am J Med Genet Part A. 2022;188:683\u20137.","journal-title":"Am J Med Genet Part A"},{"key":"1958_CR45","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.ajhg.2013.04.026","volume":"92","author":"YH Cheung","year":"2013","unstructured":"Cheung YH, Gayden T, Campeau PM, LeDuc CA, Russo D, Nguyen VH, et al. A recurrent PDGFRB mutation causes familial infantile myofibromatosis. Am J Hum Genet. 2013;92:996\u20131000.","journal-title":"Am J Hum Genet"},{"key":"1958_CR46","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.ajhg.2013.04.024","volume":"92","author":"JA Martignetti","year":"2013","unstructured":"Martignetti JA, Tian L, Li D, Ramirez MC, Camacho-Vanegas O, Camacho SC, et al. Mutations in PDGFRB cause autosomal-dominant infantile myofibromatosis. Am J Hum Genet. 2013;92:1001\u20137.","journal-title":"Am J Hum Genet"},{"key":"1958_CR47","doi-asserted-by":"publisher","first-page":"6287","DOI":"10.4238\/2014.August.15.11","volume":"13","author":"ND Linhares","year":"2014","unstructured":"Linhares ND, Freire MC, Cardenas RG, Bahia M, Puzenat E, Aubin F, et al. Modulation of expressivity in PDGFRB-related infantile myofibromatosis: a role for PTPRG? Genet Mol Res. 2014;13:6287\u201392.","journal-title":"Genet Mol Res"},{"key":"1958_CR48","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ejmg.2017.02.005","volume":"60","author":"N Murray","year":"2017","unstructured":"Murray N, Hanna B, Graf N, Fu H, Myl\u00e8ne V, Campeau PM, et al. The spectrum of infantile myofibromatosis includes both non-penetrance and adult recurrence. Eur J Med Genet. 2017;60:353\u20138.","journal-title":"Eur J Med Genet"},{"key":"1958_CR49","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1177\/1093526618787736","volume":"22","author":"R Al Qawahmed","year":"2019","unstructured":"Al Qawahmed R, Sawyer SL, Vassilyadi M, Qin W, Boycott KM, Michaud J. Infantile Myofibromatosis With Intracranial Extradural Involvement and PDGFRB Mutation: A Case Report and Review of the Literature. Pediatr Dev Pathol. 2019;22:258\u201364.","journal-title":"Pediatr Dev Pathol"},{"key":"1958_CR50","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1002\/ajmg.a.61283","volume":"179","author":"JM Weller","year":"2019","unstructured":"Weller JM, Keil VC, Gielen GH, Herrlinger U, Sch\u00e4fer N. PDGRFB mutation-associated myofibromatosis: Response to targeted therapy with imatinib. American Journal of Medical Genetics Part A. 2019;179:1895\u20137.","journal-title":"American Journal of Medical Genetics Part A"},{"key":"1958_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-023-01612-w","volume":"16","author":"Y L\u00fc","year":"2023","unstructured":"L\u00fc Y, Jiang Y, Wu H, Qi Q, Zhou X, Guo Q, et al. Prenatal genetic diagnosis of disseminated infantile myofibromatosis: a case report and literature review. BMC Med Genomics. 2023;16:185.","journal-title":"BMC Med Genomics"},{"key":"1958_CR52","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1002\/ajmg.a.38310","volume":"173","author":"M Minatogawa","year":"2017","unstructured":"Minatogawa M, Takenouchi T, Tsuyusaki Y, Iwasaki F, Uehara T, Kurosawa K, et al. Expansion of the phenotype of Kosaki overgrowth syndrome. Am J Med Genet A. 2017;173:2422\u20137.","journal-title":"Am J Med Genet A"},{"key":"1958_CR53","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1111\/cge.13192","volume":"93","author":"P Gawli\u0144ski","year":"2018","unstructured":"Gawli\u0144ski P, Pelc M, Ciara E, Jhangiani S, Jurkiewicz E, Gambin T, et al. Phenotype expansion and development in Kosaki overgrowth syndrome. Clin Genet. 2018;93:919\u201324.","journal-title":"Clin Genet"},{"key":"1958_CR54","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1002\/ajmg.a.61145","volume":"179","author":"YA Zarate","year":"2019","unstructured":"Zarate YA, Boccuto L, Srikanth S, Pauly R, Ocal E, Balmakund T, et al. Constitutive activation of the PI3K-AKT pathway and cardiovascular abnormalities in an individual with Kosaki overgrowth syndrome. Am J Med Genet A. 2019;179:1047\u201352.","journal-title":"Am J Med Genet A"},{"key":"1958_CR55","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/ajmg.a.62027","volume":"185","author":"T Takenouchi","year":"2021","unstructured":"Takenouchi T, Kodo K, Yamazaki F, Nakatomi H, Kosaki K. Progressive cerebral and coronary aneurysms in the original two patients with Kosaki overgrowth syndrome. Am J Med Genet A. 2021;185:999\u20131003.","journal-title":"Am J Med Genet A"},{"key":"1958_CR56","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1002\/ajmg.a.35984","volume":"161","author":"F Zufferey","year":"2013","unstructured":"Zufferey F, Hadj-Rabia S, De Sandre-Giovannoli A, Dufier JL, Leheup B, Schweitze C, et al. Acro-osteolysis, keloid like-lesions, distinctive facial features, and overgrowth: Two newly recognized patients with premature aging syndrome, penttinen type. American Journal of Medical Genetics Part A. 2013;161:1786\u201391.","journal-title":"American Journal of Medical Genetics Part A"}],"container-title":["European Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41431-025-01958-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-025-01958-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-025-01958-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T08:35:48Z","timestamp":1764578148000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41431-025-01958-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":56,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1958"],"URL":"https:\/\/doi.org\/10.1038\/s41431-025-01958-y","relation":{},"ISSN":["1018-4813","1476-5438"],"issn-type":[{"value":"1018-4813","type":"print"},{"value":"1476-5438","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"10 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethical approval was not required as this work was performed exclusively in vitro.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}